Stay updated on CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial

Sign up to get notified when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change represents an update in the estimated completion date for the study regarding CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies.
    Difference
    0.0%
    Check dated 2024-05-11T17:19:55.000Z thumbnail image
  7. Check
    9 days ago
    Change Detected
    Summary
    The value 04 16 04 13 04 16 04 12 has recently changed to 05 09 05 08 (Estimated) 05 09 05 06. This change likely represents an update or modification in the data related to the CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells clinical trial for children and young adults with recurrent or refractory CD19/CD22-expressing B Cell Malignancies.
    Difference
    0.6%
    Check dated 2024-05-10T08:17:59.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:19:20.000Z thumbnail image

Stay in the know with updates to CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.